[Federal Register Volume 63, Number 39 (Friday, February 27, 1998)]
[Notices]
[Page 10028]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-5049]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Allergenic Products Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Allergenic Products Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA regulatory issues.
Date and Time: The meeting will be held on March 24, 1998, 1 p.m.
to 4:30 p.m. by teleconference.
Location: Food and Drug Administration, Bldg. 29, conference room
121, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by
telephone conference call. A speaker phone will be provided in the
conference room to allow public participation in the meeting.
Contact Person: William Freas or Sheila D. Langford, Center for
Biologics Evaluation and Research (HFM-21), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12388. Please call the
Information Line for up-to-date information on this meeting.
Agenda: The committee will receive an update on the status of
standardized grasses and discuss how candidate allergens for future
standardization should be identified.
Procedure: On March 24, 1998, from 1 p.m. to 3 p.m., the meeting is
open to the public. Interested persons may present data, information,
or views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by March 18,
1998. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2 p.m. Time allotted for each presentation may
be limited. Those desiring to make formal presentations should notify
the contact person before March 18, 1998, and submit a brief statement
of the general nature of the evidence or arguments they wish to
present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their
presentation.
Closed Committee Deliberations: On March 24, 1998, from 3 p.m. to 4
p.m., the meeting will be closed to permit discussion and review of
trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).
This portion of the meeting will be closed to hear and review trade
secret and/or confidential information on pending investigational new
drugs.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 20, 1998.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 98-5049 Filed 2-26-98; 8:45 am]
BILLING CODE 4160-01-F
